Back to search

Ireland· IE-PA-PA23259/011/001

Minims Cyclopentolate Hydrochloride 1% w/v Eye Drops, solution

A cyclopentolate product containing cyclopentolate hydrochloride, registered in Ireland by Bausch + Lomb Ireland Limited. The same ATC class is registered in 16 of our 19 countries.

ATC S01FA04

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedMinims Cyclopentolate Hydrochloride 1…ATCS01FA04REGISTER NO.IE-PA-PA23259/011/001PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Cyclopentolate is registered in 16 of 19 countries.

Countries holding a registration under ATC S01FA04 (cyclopentolate), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 8 of them publish a price we can compare per daily dose

Cyclopentolate · ATC S01FA04

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Cyclopentolate hydrochloride
Manufacturer
Bausch + Lomb Ireland Limited
Country
Ireland (IE)
ATC code
S01FA04
ATC class
Cyclopentolate
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA23259/011/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

3 interactions on record for cyclopentolate.

Graded by severity as the source publishes them — 3 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cyclopentolate · interactions on record

3 records

  • 3 moderate

Most severe, free to view

  • PhenylephrineC01CA06moderate
  • PhysostigmineS01EB05moderate
  • PhysostigmineV03AB19moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cyclopentolate in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cyclopentolate products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Belgium · Cyclogyl, Minims Cyclopentolaathydrochloride Bausch + Lomb Ireland Limited
  • Bulgaria · Цикловижън
  • Cyprus · Cyclogyl
  • Czechia · Cyclopentolate Olikla
  • Germany · Cyclopentolat Alcon, Zyklolat Edo
  • Denmark · Cyclogyl
  • Spain · Colirofta Ciclopléjico
  • Finland · Oftan Syklo
  • France · Skiacol
  • Greece · Cyclogyl
  • Hungary · Humapent
  • Iceland · Cyclogyl
  • Italy · Ciclolux, Plegik
  • Lithuania · Cyclogyl
  • Luxembourg · Minims, Minims Cyclopentolate Chlorhydrate Bausch + Lomb Ireland Limited
  • Malta · Minims Cyclopentolate Hydrochloride Bausch + Lomb Ireland
  • Netherlands · Cyclogyl, Minims Cyclopentolaathydrochloride Bausch + Lomb Ireland Limited
  • Norway · Cyclopentolat Bausch + Lomb Ireland Limited
  • Poland · Cykloftyal
  • Portugal · Cicloplegicedol, Midriodavi
  • Sweden · Cyclogyl, Cyclopentolat Bausch & Lomb
  • Slovakia · Cyclopentolate Olikla

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b82ff85d-c882-48c7-8fd6-f24bdd7de9e7
GET /v1/drugs/b82ff85d-c882-48c7-8fd6-f24bdd7de9e7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Eye drops, solution",
  "routes": [
    "Ocular use"
  ],
  "source": "hpra",
  "atc_all": [
    "S01FA",
    "S01FA04"
  ],
  "strength": null,
  "pa_number": "PA23259/011/001",
  "substances": [
    "Cyclopentolate hydrochloride"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Not marketed",
  "authorised_at": "01/04/1979",
  "dispensing_status": "Product subject to prescription which may be renewed (B)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about cyclopentolate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.